Want to see AU:EYE full AI Analyst Report?
EYE Stock Chart & Stats
AU$0.14
>-AU$0.01(-3.23%)
At close: 4:00 PM EDT
AU$0.14
>-AU$0.01(-3.23%)
Day’s Range― - ―
52-Week RangeAU$0.10 - AU$0.21
Previous CloseN/A
Volume91.16K
Average Volume (3M)134.81K
Market Cap
AU$42.74M
Enterprise ValueAU$31.34M
Total Cash (Recent Filing)AU$964.00K
Total Debt (Recent Filing)AU$2.39M
Price to Earnings (P/E)―
Beta0.72
Next Earnings
Mar 02, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield185.34%
Share Statistics
EPS (TTM)-0.02
Shares Outstanding284,921,080
10 Day Avg. Volume136,783
30 Day Avg. Volume134,807
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)2.09
Price to Sales (P/S)0.86
P/FCF Ratio-8.90
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)AU$42.35M
Bulls Say, Bears Say
Bulls Say
Revenue GrowthRevenue has expanded substantially over five years, indicating growing commercial scale for Nova Eye Medical’s ophthalmic device business. Continued top-line expansion can support operating leverage, broader customer adoption, and greater capacity to fund product development as the company moves toward profitability.
Gross MarginThe sharp improvement in gross margin suggests a stronger economic profile for the company’s products and provides more revenue available to cover operating costs. Maintaining margins near recent levels would improve the path to breakeven and support more efficient reinvestment in commercial growth.
Conservative LeverageLow debt and modest debt-to-equity reduce financial pressure while the business continues scaling and remains loss-making. This conservative leverage profile preserves flexibility to manage working capital, invest in ophthalmic products, and address near-term volatility without excessive interest or refinancing burdens.
Bears Say
Persistent LossesNova Eye Medical remains unprofitable despite narrowing losses, so revenue growth has not yet translated into sustainable earnings. Continued negative margins limit internally generated capital, increase dependence on external funding, and leave the company exposed if the improvement toward breakeven slows.
Negative Cash GenerationPersistent negative operating and free cash flow shows that the business is still consuming cash to operate and invest. Although operating outflow improved in 2026, ongoing burn can require additional funding and may constrain product investment until cash generation becomes sustainably positive.
Shrinking Equity BaseThe substantial reduction in equity is consistent with cumulative losses and indicates that balance sheet resources have been eroded over time. Even with low leverage, continued equity decline could reduce financial resilience and limit the company’s ability to fund growth without further capital support.
Nova Eye Medical News
EYE FAQ
What was Nova Eye Medical’s price range in the past 12 months?
Nova Eye Medical lowest share price was AU$0.10 and its highest was AU$0.20 in the past 12 months.
What is Nova Eye Medical’s market cap?
Nova Eye Medical’s market cap is AU$42.74M.
When is Nova Eye Medical’s upcoming earnings report date?
Nova Eye Medical’s upcoming earnings report date is Mar 02, 2027 which is in 129 days.
How were Nova Eye Medical’s earnings last quarter?
Nova Eye Medical released its earnings results on Aug 26, 2026. The company reported -AU$0.003 earnings per share for the quarter.
Is Nova Eye Medical overvalued?
According to Wall Street analysts Nova Eye Medical’s price is currently Overvalued.
Does Nova Eye Medical pay dividends?
Nova Eye Medical pays a Weekly dividend of AU$0.414 which represents an annual dividend yield of 185.34%. See more information on Nova Eye Medical dividends here
What is Nova Eye Medical’s EPS estimate?
Nova Eye Medical’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Nova Eye Medical have?
Nova Eye Medical has 284,921,080 shares outstanding.
What happened to Nova Eye Medical’s price movement after its last earnings report?
Nova Eye Medical reported an EPS of -AU$0.003 in its last earnings report. Following the earnings report the stock price went up 1.429%.
Which hedge fund is a major shareholder of Nova Eye Medical?
Currently, no hedge funds are holding shares in AU:EYE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Nova Eye Medical Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:EYE Sentiment 92%
Sector Average 66%
Sector Average 66%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
―
20 days / 200 days
Momentum
-94.40%
12-Months-Change
Fundamentals
Return on Equity
-28.79%
Trailing 12-Months
Asset Growth
-13.89%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Nova Eye Medical
Nova Eye Medical Limited specializes in the creation, advancement, distribution, marketing, sale, and servicing of surgical equipment dedicated to treating glaucoma. Its diverse product line features iTrack, a surgical system engineered to decrease intraocular pressure (IOP) in adult patients with open-angle glaucoma, and iTrack Advance, an innovative system promoting natural ocular fluid drainage. Furthermore, the company provides Molteno3, a glaucoma drainage device for individuals suffering from severe or intricate forms of the condition, alongside 2RT, a proprietary laser technology employed to address early to intermediate stages of age-related macular degeneration. With a presence spanning Australia, the United States, Europe, the Asia Pacific, and other international markets, the company, originally established in 1985 as Ellex Medical Lasers Limited, officially became Nova Eye Medical Limited in July 2020. Its corporate headquarters are situated in Kent Town, Australia.
Technical Analysis
Cochlear
―
Compumedics Limited
―
Somnomed Limited
―
EMvision Medical Devices Ltd.
―
Control Bionics Ltd.
―